- Home
- GHLD vs CVAC Comparison
GHLD vs CVAC Comparison
Compare GHLD & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GHLD
- CVAC
- Stock Information
- Founded
- GHLD 1960
- CVAC 2000
- Country
- GHLD United States
- CVAC Germany
- Employees
- GHLD N/A
- CVAC N/A
- Industry
- GHLD Finance: Consumer Services
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- GHLD Finance
- CVAC Health Care
- Exchange
- GHLD Nasdaq
- CVAC Nasdaq
- Market Cap
- GHLD 1.2B
- CVAC 1.2B
- IPO Year
- GHLD 2020
- CVAC 2020
- Fundamental
- Price
- GHLD $19.98
- CVAC $5.40
- Analyst Decision
- GHLD Hold
- CVAC Hold
- Analyst Count
- GHLD 6
- CVAC 3
- Target Price
- GHLD $18.10
- CVAC $6.83
- AVG Volume (30 Days)
- GHLD 71.6K
- CVAC 685.0K
- Earning Date
- GHLD 08-07-2025
- CVAC 08-15-2025
- Dividend Yield
- GHLD 3.76%
- CVAC N/A
- EPS Growth
- GHLD N/A
- CVAC N/A
- EPS
- GHLD 0.42
- CVAC 1.01
- Revenue
- GHLD $1,125,872,000.00
- CVAC $599,540,810.00
- Revenue This Year
- GHLD $5.56
- CVAC N/A
- Revenue Next Year
- GHLD $21.57
- CVAC $24.04
- P/E Ratio
- GHLD $47.79
- CVAC $5.36
- Revenue Growth
- GHLD 23.19
- CVAC 675.15
- 52 Week Low
- GHLD $11.21
- CVAC $2.37
- 52 Week High
- GHLD $23.57
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- GHLD 63.65
- CVAC 46.42
- Support Level
- GHLD $19.78
- CVAC $5.41
- Resistance Level
- GHLD $19.94
- CVAC $5.48
- Average True Range (ATR)
- GHLD 0.42
- CVAC 0.05
- MACD
- GHLD -0.07
- CVAC -0.02
- Stochastic Oscillator
- GHLD 5.01
- CVAC 3.13
About GHLD Guild Holdings Company
Guild Holdings Co is a growth-oriented mortgage company. It operates in two segments; The origination segment operates its loan origination business throughout the United States. It is responsible for loan origination, acquisition, and sale activities. This segment is further divided into retail and correspondent channel, and The servicing segment provides a steady stream of cash flow to support the origination segment more importantly it allows for the Company to build long-standing client relationships that drive repeat and referral business back to the origination segment to recapture the client's next mortgage transaction. It is responsible for the servicing activities of all loans in its servicing portfolio. It generates a majority of its revenue from the Origination segment.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.